entertainment -WSS

entertainment

author：leisure time 2025-09-14 06:50:07 - browse：57

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Organ aging and disease risk measured by new blood test

explore

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Obesity now affects over 1 billion people worldwide, study finds

How to address the problem of discarded donor organs

Pfizer highlights cancer drugs it thinks could reignite investor interest

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Diagnostic tests are hitting their mathematical limits

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

U.K. Biobank has 500,000 peoples' genome sequences available

Moonlake's readout produced a cash windfall. Risks remain

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Medical records are filled with copy

ReNAgade cuts staff seven months after raising $300 million

At least 13 dead in Texas as scorching temps continue

Rep. Raul Ruiz on the physician shortage and more

Cancer drug shortages should be causing more outrage

Rep. Raul Ruiz on the physician shortage and more

entertainment

Medical device lobby: We're tired of waiting on Medicare coverage

Pediatric cancer treatments threatened by a new FDA policy

ReNAgade cuts staff seven months after raising $300 million

In search for therapies for solid tumors, companies turn to claudin

Medical device lobby: We're tired of waiting on Medicare coverage

FogPharma raises $145 million in rare Series E round

explore

focus

explore

leisure time